Aktie AUDENTES THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Audentes Therapeutics, Inc.

Aktien

US05070R1041

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement
Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.
Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.
Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy
Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy
Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources
Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina
AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
Audentes Therapeutics, Inc. Announces Management Changes
Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Biotechnology Index
Astellas US Holding, Inc. completed the acquisition of Audentes Therapeutics, Inc..
Takeda Pharmaceutical : Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Roche : dives deeper into gene therapy with $1.15 billion Sarepta licensing deal
AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
Japanese shares slip on concerns of longer trade war
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten Audentes Therapeutics, Inc.
  5. Andere Sprachen